DELAFIELD, Wis. (Stockpickr) -- As part of a daily routine as an active trader or investor, one should always be tracking the stocks in the market that are making the biggest percentage gains and the biggest percentage losses.

Stocks that are making large moves to the upside are favorites among short-term traders because they can jump into these names and try to capture some of that massive volatility. Stocks that are making big-percentage moves either up or down are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst downgrade.

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. If you time your trade correctly, combining with fundamental trends, discipline and sound money management, you will be well on your way to investment success.

With that in mind, let's take a closer look at a several stocks under $10 that are making large moves to the upside.

Xoma

Xoma (XOMA) - Get Report discovers and develops antibody-based therapeutics in the U.S., Europe and the Asia Pacific. This stock is trading up 1.2% to $4.03 in Tuesday's trading session.

Tuesday's Range: $3.88-$4.12
52-Week Range: $3.22-$6.45
Tuesday's Volume: 695,000
Three-Month Average Volume: 2.46 million

From a technical perspective, XOMA is spiking modestly higher here right above some near-term support levels at $3.77 to its 50-day moving average of $3.67 with lighter-than-average volume. This spike to the upside on Tuesday briefly pushed shares of XOMA right into its 200-day moving average of $4.14. That move is now starting to push shares of XOMA within range of triggering a major breakout trade above some key near-term overhead resistance levels. That trade will hit if XOMA manages to take out its 200-day at $4.14 and then once it clears some more key near-term overhead resistance levels at $4.28 to $4.33 with high volume.

Traders should now look for long-biased trades in XOMA as long as it’s trending above some near-term support levels at $3.77 or above its 50-day at $3.67 and then once it sustains a move or close above those breakout levels with volume that hits near or above 2.46 million shares. If that breakout triggers soon, then XOMA will set up to re-test or possibly take out its next major overhead resistance levels at $4.50 to $4.75, or even $5.

Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics (BCLI) - Get Report, a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis, Parkinson disease and multiple sclerosis. This stock is trading up 2% to $4.42 in Tuesday's trading session.

Tuesday's Range: $4.27-$4.45
52-Week Range: $2.81-$8.47
Tuesday's Volume: 59,000
Three-Month Average Volume: 955,112

From a technical perspective, BCLI is spiking modestly higher here right above its 200-day moving average of $4.18 and above its 50-day moving average of $4.05 with lighter-than-average volume. This spike to the upside on Tuesday is starting to push shares of BCLI within range of triggering a major breakout trade above some key near-term overhead resistance levels. That trade will hit if BCLI manages to take out some key overhead resistance levels at $4.45 to $4.65 with high volume.

Traders should now look for long-biased trades in BCLI as long as it's trending above its 200-day at $4.18 or its 50-day at $4.05 and then once it sustains a move or close above those breakout levels with volume that hits near or above 955,112 shares. If that breakout begins soon, then BCLI will set up to re-test or possibly take out its next major overhead resistance levels at $6 to around $6.50.

Sunesis Pharmaceuticals

Sunesis Pharmaceuticals (SNSS) - Get Report, a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. This stock is trading up 1.1% to $2.62 in Tuesday's trading session.

Tuesday's Range: $2.54-$2.67
52-Week Range: $1.00-$8.46
Tuesday's Volume: 960,000
Three-Month Average Volume: 1.05 million

From a technical perspective, SNSS is moving modestly higher here right above its 50-day moving average of $2.36 with strong upside volume flows. This move to the upside on Tuesday is starting to push shares of SNSS within range of triggering a major breakout trade above some key near-term overhead resistance levels. That trade will hit if SNSS manages to take out some key near-term overhead resistance levels at $2.74 to $2.94 with high volume.

Traders should now look for long-biased trades in SNSS as long as it's trending above its 50-day moving average of $2.36 or above more support at around $2 and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.05 million shares. If that breakout materializes soon, then SNSS will set up to re-fill some of its previous gap-down-day zone from October that stared near $7 a share.

Endocyte

Endocyte (ECYT) - Get Report, a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the U.S. This stock is trading up 6% to $6.42 in Tuesday's trading session.

Tuesday's Range: $6.04-$6.46
52-Week Range: $5.01-$29.49
Tuesday's Volume: 485,000
Three-Month Average Volume: 536,220

From a technical perspective, ECYT is ripping sharply higher here right above some near-term support at $5.84 and back above its 200-day moving average of $6.28 with decent upside volume flows. This sharp move to the upside on Tuesday is quickly pushing shares of ECYT within range of triggering a major breakout trade above some key overhead resistance levels. That trade will hit if ECYT manages to take out some key overhead resistance levels at $6.46 to $6.76 and then above $6.89 with high volume.

Traders should now look for long-biased trades in ECYT as long as it's trending above Tuesday's intraday low of $6.04 or above more support at $5.84 and then once it sustains a move or close above those breakout levels with volume that hits near or above 536,220 shares. If that breakout hits soon, then ECYT will set up to re-test or possibly take out its next major overhead resistance levels at $8.09 to $9.

This article is commentary by an independent contributor. At the time of publication, the author held no positions in the stocks mentioned.